Last reviewed · How we verify
NCT06606236
Neuropeptide Y Regulates Neurogenic Pulp Inflammation
NA trial testing H2O2 at 35% for 8 minutes in Neurogenic Inflammation in 40 participants. Completed in 28 February 2024.
28 February 2024
Quick facts
| Lead sponsor | Institucion Universitaria Colegios de Colombia |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | diagnostic |
| Enrollment | 40 |
| Start date | 5 February 2024 |
| Primary completion | 28 February 2024 |
| Estimated completion | 28 February 2024 |
| Sites | 1 location across Colombia |
Drugs / interventions tested
- H2O2 at 35% for 8 minutes
- H2O2 at 40% for 20 minutes
- H2O2 at 25% plus cold blue light for 15 minutes
Conditions studied
- Neurogenic Inflammation — all drugs for Neurogenic Inflammation →
- Dental Pulp Disease — all drugs for Dental Pulp Disease →
Sponsor
Institucion Universitaria Colegios de Colombia — full company profile →
Who can join
Adults 18 to 27, any sex, with Neurogenic Inflammation or Dental Pulp Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Objective. This study assessed the neuropeptide Y (NPY) expression in healthy human dental pulp following tooth bleaching with three in-office hydrogen peroxide-based systems: Opalescence Boost© (Ultradent Products, South Jordan, UT), Pola Office© (SDI, Victoria, Australia), and Zoom© (Zoom! Bleaching System; Discuss Dental, Culver City, CA). Materials and Methods. Forty dental pulps were collected from healthy premolars scheduled for extraction for orthodontic reasons. Teeth were divided into four groups containing ten healthy premolars each: Control group (n= 10): the teeth were not exposed to dental bleaching agents (healthy pulps assessed for normal/basal NPY values). Pola Office system group (n= 10): application of Pola office (35% H2O2) for 8 minutes. Opalescent Boost system group (n= 10): application of Opalescent Boost (40% H2O2) for 20 minutes. Zoom system group (n= 10): application of Zoom! (25% H2O2 + cold blue light) for 15 minutes. The investigators rigorously followed the manufacturer's instructions for all bleaching systems. Following the extractions, the pulpal tissue was collected, placed in a 4% formaldehyde solution in Eppendorf tubes, and processed. NPY levels were measured using enzyme-linked immunosorbent assay (ELISA).
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Neuropeptide Y regulation of dental pulp neurogenic inflammation provoked by tooth bleaching agents: a descriptive comparative clinical study.
Caviedes-Bucheli J, Ríos-Osorio N, Pérez-Villota M, Aucú-Miño K, et al · · 2026 · PMID 41680589 · DOI 10.5395/rde.2026.51.e10 -
Neuropeptide Y regulation of dental pulp neurogenic inflammation provoked by tooth bleaching agents
Caviedes-Bucheli J, Pérez-Villota M, Aucú-Miño K, Escobar-Mafla D, et al · · 2024 · DOI 10.21203/rs.3.rs-5375900/v1
Verify or expand the search:
- PubMed search for NCT06606236
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Institucion Universitaria Colegios de Colombia trials
Trials by the same sponsor.
- NCT06482593 — Periapical Healing in Response to Endodontically Treated Teeth With Different Sealing Cement · Phase 4 · active not recruiting
- NCT04881786 — Calcitonin Gene-related Peptide Expression in Human Periodontal Ligament · NA · completed
- NCT03680534 — 3D Analysis of Root Canal Conformation · NA · completed
- NCT03804034 — Importance of Neurogenic Inflammation in the Angiogenic Response of the Dental Pulp as a Defensive Response · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06606236 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institucion Universitaria Colegios de Colombia
- Last refreshed: 23 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06606236.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing